ClinicalTrials.gg
CompletedNCT07382908Updated Oct 16, 2026

Bioequivalence Study of BGM0504 Injection

A Phase 1 interventional study of BGM0504 Injection multi-dose pen and BGM0504 Injection single-dose pen in Overweight/Obesity, sponsored by BrightGene Bio-Medical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by BrightGene Bio-Medical Technology Co., Ltd. · Phase 1, Interventional, and Treatment

Updated Oct 16, 2026Now CompletedInterventions changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing BGM0504 in Obesity — none open to participants now, none under way, none of them phase 3. BGM0504 · Obesity.

Enrollment
2nd of 10
144 · median 78
Started
2025
with 5 others
Phase 1
6 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
8 of 10
BrightGene Bio-Medical Technology Co., Ltd.

Among the 10 studies testing BGM0504 in Obesity, this one is the 2nd largest by enrollment, is one of 6 that started in 2025, is one of 6 in phase 1, and was the 9th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 10 studies testing BGM0504 in Obesity is open now. The open studies under Obesity, anywhere →

Where they have run

About BGM0504

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing BGM0504 in Obesity as a file.
02

Study summary

This is a study to evaluate the bioequivalence of a single subcutaneous injection of BGM0504 multi-dose pen (experimental formula T1) and BGM0504 single-dose pen (experimental formula T2) with BGM0504 single-dose pen (reference formula R).

03

Conditions studied

  • Overweight/Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 144 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

BrightGene Bio-Medical Technology Co., Ltd. is the lead sponsor of 18 studies on the registry; 3 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-55 years (inclusive).
  • Male weight ≥50 kg, female weight ≥45 kg, and overweight (24.0 ≤ \< 28.0 kg/m²) or obese (BMI ≥ 28.0 kg/m²).
  • From signing the ICF until 3 months after dosing, no pregnancy plan and willing to use effective to avoid pregnancy or causing partner pregnancy, and no plan for sperm/egg donation.
  • The participant fully understands the trial purpose, nature, methods, and potential adverse reactions, can complete the trial according to the protocol, has good living habits, can maintain good communication with the investigator, and voluntarily signs the ICF.

Exclusion criteria

Exclusion Criteria:

  • History of severe allergies or severe specific allergic diseases/history (asthma, urticaria, eczematous dermatitis, etc.) or allergic constitution (allergic to two or more foods or drugs), known or suspected allergy to any of BGM0504 Injection.
  • Previous diagnosis of type 1 or type 2 diabetes, or abnormal at screening.
  • Family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 syndrome.
  • History of acute/chronic pancreatitis, pancreatic injury, or other high-risk factors for pancreatitis.
  • Past or screening findings of digestive system diseases that may increase participant risk.
  • Positive for , antibody, syphilis antibody, or antibody at screening.
  • Participation in any drug or medical device clinical trial and receiving product/device intervention within 3 months prior to screening.
  • Consumption or plan to consume specific foods (including pitaya, mango, grapefruit, pomelo or their juices, high-purine foods like animal organs, seafood, chocolate) or beverages containing caffeine/alcohol within 48 hours before dosing; or unwilling to stop consuming these during the in-house period.
  • Pregnant or breastfeeding women, or positive pregnancy test at screening.
  • Any other condition considered by the investigator as unsuitable for participation or participant withdrawal due to personal reasons..
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    BGM0504 Injection multi-dose pen

    Drug: BGM0504 Injection multi-dose pen

  • Experimental
    BGM0504 Injection single-dose pen

    Drug: BGM0504 Injection single-dose pen

  • Active comparator
    BGM0504 Injection single-dose pen-2

    Drug: BGM0504 Injection single-dose pen

Interventions

07

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax)

    Peak Plasma Concentration (Cmax)

    Time frame: 0 to 672 hours

  2. Area under the plasma concentration versus time curve (AUC)0-t

    Area under the plasma concentration versus time curve (AUC)0-t

    Time frame: 0 to 672 hours

Secondary outcomes

  1. Monitor all the adverse event

    Monitor all the adverse event was assessed by the investigator.

    Time frame: 29 days

08

Study locations

1 site
  • Hangzhou First People's Hospital
    Hangzhou, Zhejiang 310006, China
09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Apr 2026, 3 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Feb 2026 → Apr 2026 and completion Feb 2026 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Feb 3, 2026
StartActual
Dec 29, 2025
Primary completionActual
Apr 9, 2026was Feb 2026
CompletionActual
Apr 9, 2026was Feb 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 15, 2026
Start date
Dec 23, 2025→Dec 29, 2025
Oct 15, 2026
Primary completion
Feb 12, 2026→Apr 9, 2026 (actual)
Oct 15, 2026
Study completion
Feb 12, 2026→Apr 9, 2026 (actual)
Oct 15, 2026
Interventions
Arms added: BGM0504 Injection multi-dose pen·BGM0504 Injection single-dose pen·BGM0504 Injection single-dose pen-2; arms removed: Group A·Group B·Group C
Oct 16, 2026
Show all 2 updates
  1. Oct 16, 2026
    Interventions Arms added: BGM0504 Injection multi-dose pen·BGM0504 Injection single-dose pen·BGM0504 Injection single-dose pen-2; arms removed: Group A·Group B·Group C
  2. Oct 15, 2026
    Recruiting→Completed
    Start date Dec 23, 2025→Dec 29, 2025
    Primary completion Feb 12, 2026→Apr 9, 2026 (now actual)
    Study completion Feb 12, 2026→Apr 9, 2026 (now actual)
    + 4 other changes: verification date, responsible party, site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07382908
Responsible party
Sponsor
First posted
Feb 3, 2026
Start date
Dec 29, 2025
Primary completion
Apr 9, 2026
Completion
Apr 9, 2026
Last update
Oct 16, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BGM0504

Start the discussion